Rafferty Asset Management
ARQT icon

Rafferty Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Rafferty Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Sell
80,777
-102,247
-56% -$2.38M ﹤0.01% 629
2026
Q1 		$4.31M Buy
183,024
+10,958
+6% +$280K 0.02% 438
2025
Q4 		$5M Buy
172,066
+23,771
+16% +$609K 0.02% 435
2025
Q3 		$2.8M Sell
148,295
-6,056
-4% -$95.5K 0.01% 563
2025
Q2 		$2.16M Sell
154,351
-6,016
-4% -$84.3K 0.01% 587
2025
Q1 		$2.51M Sell
160,367
-49,970
-24% -$704K 0.01% 516
2024
Q4 		$2.93M Sell
210,337
-66,481
-24% -$728K 0.01% 535
2024
Q3 		$2.57M Buy
276,818
+17,340
+7% +$171K 0.01% 574
2024
Q2 		$2.41M Sell
259,478
-562,983
-68% -$5.09M 0.01% 592
2024
Q1 		$8.15M Buy
+822,461
New +$6.14M 0.03% 342
2023
Q4 		– Sell
-419,309
Closed -$2.23M – 1075
2023
Q3 		$2.23M Sell
419,309
-80,613
-16% -$686K 0.01% 582
2023
Q2 		$4.76M Buy
499,922
+195,216
+64% +$2.17M 0.03% 425
2023
Q1 		$3.35M Buy
304,706
+1,577
+0.5% +$22.8K 0.02% 482
2022
Q4 		$4.49M Buy
303,129
+129,146
+74% +$2.26M 0.04% 393
2022
Q3 		$3.33M Buy
173,983
+131,606
+311% +$2.98M 0.04% 400
2022
Q2 		$903K Sell
42,377
-14,882
-26% -$305K 0.01% 682
2022
Q1 		$1.1M Buy
57,259
+409
+0.7% +$6.92K 0.01% 758
2021
Q4 		$1.18M Buy
56,850
+26,627
+88% +$530K 0.01% 802
2021
Q3 		$722K Sell
30,223
-7,538
-20% -$172K ﹤0.01% 957
2021
Q2 		$1.03M Sell
37,761
-3,932
-9% -$111K 0.01% 882
2021
Q1 		$1.21M Buy
41,693
+34,130
+451% +$1.07M 0.01% 730
2020
Q4 		$213K Buy
+7,563
New +$185K ﹤0.01% 974

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management's ARQT Position: Q2 2026 in Review

Rafferty Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 56% in Q2 2026, selling an estimated $2.38M and leaving 80,777 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Rafferty Asset Management first reported a position in ARQT in Q4 2020 and has held it in 22 quarters since. The position peaked at $8.15M in Q1 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Rafferty Asset Management held 80,777 shares of Arcutis Biotherapeutics worth $2.12M as of Q2 2026.
  • Rafferty Asset Management sold 102,247 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.38M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #629 holding.
  • Rafferty Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 22 quarters since.
  • Rafferty Asset Management's Arcutis Biotherapeutics position peaked at $8.15M in Q1 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.